Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors

Key Points

• Azenosertib effectively inhibits WEE1 kinase, demonstrating broad antitumor activity across different solid tumors.
• Optimized dosing schedules have been proposed based on enhancements in the efficacy of azenosertib treatment.
• The study involves investigating the intermittent dosing schedule for azenosertib in various cancer models.
• Findings contribute to understanding how azenosertib can be utilized for better cancer treatment outcomes.